-
Prone Partial Breast Irradiation (PBI): A Prospective Randomized Trial Comparing Five Versus Three Fractions
If you have been diagnosed with Stage 0 or I breast cancer, also known as ductal carcinoma in situ (DCIS) or T1 breast cancer, you ...
-
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2 Stage II IIIB or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
If you have been diagnosed with locally advanced cervical or vaginal cancer, you may qualify for this Phase II study evaluating the investigational drug triapine ... -
PRECISION (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer.
If you have been diagnosed with breast cancer and are between the ages of 50 years and 75 years old, you may qualify for this ... -
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to determine whether there is any benefit of regional radiotherapy and to compare good and bad effects of not ... -
A RANDOMIZED PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER
The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the ... -
Feasibility study to treat lung cancer with the permanently implantable LDR CivaSheet
If you have been diagnosed with non-smail cell lung cancer (NSCLC), you may qualify for this study evaluating the usefulness of the brachytherapy source - CivaSheet ... -
A Phase 2 Open-label Multicenter Study of an Immunotherapeutic Treatment DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Selected Advanced and Recurrent Solid Tumours.
In this study, we are trying to determine the safety and ability of an investigational product, called DPX Survivac, to help the immune system fight ... -
A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
If you have been diagnosed with BCG unresponsive, high-risk, non-muscle invasive bladder cancer, you may qualify for this study. The main purpose of the study ... -
The OVAL Study: A Randomized Controlled Double-Arm Open-Label Multi-Center Study of VB-111 Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
You are being asked to take part in this study because you have recurrent, platinum-resistant ovarian cancer. This means your ovarian cancer has grown or ... -
A Phase I/II study Evaluating the Dosing Safety Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer
You are being asked to take part in this study because you have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and you ...